Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) has reported earnings for its third fiscal quarter (ending September 30) of $0.83 versus $1.01 for the same period a year ago — a decline of -18%. For the latest four quarters through September 30, E.P.S. were $3.25 versus $2.80 for the same period a year ago — an increase of 16%.
Recent Price Action
Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) stock closed at $53.40 on 11/6/24 after a large increase of 3.6%. Moreover, unusually high trading volume at 193% of normal accompanied the advance. The stock has risen 4.4% during the last week and has performed in line with the market over the last nine months.
Current PriceTarget Research Rating
AMPH is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Amphastar Pharmaceuticals has a current Value Trend Rating of C (Neutral). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Amphastar Pharmaceuticals has a neutral Power Rating of 55 and a neutral Appreciation Score of 58, and the Neutral Value Trend Rating results.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment